MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14796694.2026.2701490

Медицинская библиотека · Future oncology (London, England) · 2026

Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial.

Liu Ting, Dan Xiao, Li Qing, Wang Peipei, Chen Yueyun, Tian Jiangfang, Lin Zhen, Hu Yang, Shi Huashan, Ding Zhenyu

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

AIMS: To evaluate the efficacy and safety of neoadjuvant concurrent chemoradiotherapy (CCRT) utilizing nedaplatin and paclitaxel in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

PATIENTS &

METHODS

Locally advanced ESCC patients received two cycles of nedaplatin plus paclitaxel or albumin-bound paclitaxel with concurrent radiotherapy (41.4-50.4 Gy) as neoadjuvant treatment. Immunohistochemical profiling was performed on biopsies and surgical specimens. The primary endpoint was the pathological complete response (pCR) rate.

RESULTS

Among 49 enrolled patients, 33 underwent surgery, yielding a pCR rate of 30.3%. Overall survival was inferior in resected patients with positive postoperative lymph nodes (HR 3.92, 95% CI 1.30-11.80, p = 0.02, log-rank p = 0.009). Higher FOXP3 expression before (HR 0.14, 95% CI 0.02-1.26, p = 0.08, log-rank p = 0.041) and after (HR 0.23, 95% CI 0.07-0.84, p = 0.03, log-rank p = 0.015) treatment nominally contributed to favorable outcomes. Upregulated TIGIT post-treatment trended toward a poorer prognosis in this surgical cohort (HR 7.10, 95% CI 0.79-63.65, p = 0.08, log-rank p = 0.041).

CONCLUSION

Neoadjuvant nedaplatin and paclitaxel-based CCRT demonstrates encouraging preliminary antitumor efficacy. Tumor microenvironment profiling highlights FOXP3 and TIGIT dynamics as potential prognostic indicators. These hypothesis-generating insights warrant further validation in large-scale, randomized controlled trials. Clinical trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR1900024628. Date of registration: 19 July 2019.

Для цитирования: Liu Ting, Dan Xiao, Li Qing, Wang Peipei, Chen Yueyun, Tian Jiangfang, Lin Zhen, Hu Yang, Shi Huashan, Ding Zhenyu. Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial.. Future oncology (London, England). 2026. DOI: 10.1080/14796694.2026.2701490.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.